Georges Gemayel Sells 8,787 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 8,787 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the sale, the director directly owned 27,277 shares of the company’s stock, valued at $1,445,681. The trade was a 24.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Georges Gemayel also recently made the following trade(s):

• On Thursday, March 5th, Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00.

Supernus Pharmaceuticals Trading Up 0.6%

Shares of SUPN stock traded up $0.30 during trading hours on Monday, reaching $54.17. 799,891 shares of the company’s stock were exchanged, compared to its average volume of 785,366. The stock’s 50 day moving average is $50.99 and its 200-day moving average is $48.82. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -79.66, a P/E/G ratio of 1.67 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SUPN shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Stifel Nicolaus upped their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Finally, Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $62.17.

Institutional Trading of Supernus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Sit Investment Associates Inc. increased its holdings in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after purchasing an additional 250 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the period. Arizona State Retirement System lifted its holdings in shares of Supernus Pharmaceuticals by 1.7% during the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after purchasing an additional 277 shares during the period. Hantz Financial Services Inc. lifted its stake in Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the period. Finally, Maryland State Retirement & Pension System boosted its holdings in shares of Supernus Pharmaceuticals by 3.6% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.